IN ADULT PATIENTS WITH GENERALIZED PUSTULAR PSORIASIS (GPP)
Control the danger of GPP flares like never before2-4
SPEVIGO® is the first EMA-approved treatment for GPP flares. With SPEVIGO®, 54.3% of patients achieved complete pustular clearance* at Week 1.1,4
The only treatment to block the key inflammatory pathway in GPP by targeting the IL-36 receptor1,4,5
With SPEVIGO®, 54.3% of patients achieved complete pustular clearance* at Week 11,4
*Pustular clearance defined as GPPGA pustulation subscore of 0 (no visible pustules).1
EMA=European Medicines Agency; GPPGA=Generalized Pustular Psoriasis Physician Global Assessment; IL-36=interleukin-36; MOA=mechanism of action.
References
-
Local SPEVIGO® Summary of Product Characteristics. Boehringer Ingelheim Pharmaceuticals, Inc; June 2023.
-
Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919. doi:10.1080/1744666X.2019.1648209
-
Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37-42. doi:10.2147/PTT.S181808
-
Bachelez H, Choon SE, Marrakchi S, et al; for the Effisayil 1 Trial Investigators. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563
-
Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120. doi:10.1016/j.jaci.2016.08.056